Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 5/20 | 0.42 |
| ▸ | CTSK | P43235 | 5/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | APLNR | P35414 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1222348 | 1.00 | TDP1 (0.49) | TDP1MEN1GAAKMT2ACTSS | |
| SCHEMBL1222350 | 1.00 | TDP1 (0.49) | TDP1MEN1GAAKMT2ACTSS | |
| SCHEMBL570033 | 0.90 | MEN1 (0.50) | TDP1MEN1GAAKMT2ACTSS | |
| SCHEMBL7755318 | 0.88 | TDP1 (0.42) | TDP1MEN1GAAKMT2ACTSS | |
| SCHEMBL14721982 | 0.85 | TDP1 (0.50) | TDP1MEN1GAAKMT2ACTSS | |
| SCHEMBL16379307 | 0.85 | MEN1 (0.46) | TDP1MEN1GAAKMT2ACTSS | |
| SCHEMBL13960156 | 0.85 | MEN1 (0.46) | TDP1MEN1GAAKMT2ACTSS | |
| SCHEMBL2369074 | 0.85 | MEN1 (0.46) | TDP1MEN1GAAKMT2ACTSS | |
| SCHEMBL5352030 | 0.85 | MEN1 (0.46) | TDP1MEN1GAAKMT2ACTSS | |
| SCHEMBL12880606 | 0.85 | MEN1 (0.46) | TDP1MEN1GAAKMT2ACTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092053-A1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4681774-A2 | KHK INHIBITORS | Gilead Sciences, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20250388606-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4313967-B1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2025-11-12 | — | — | EP | disclosed |
| US-12410160-B2 | KHK inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-12398154-B2 | Azaquinazoline pan-KRas inhibitors | Mirati Therapeutics, Inc. (US) | 2025-08-26 | — | — | US | disclosed |
| WO-2024200838-A1 | NEW ODILORHABDINS ANALOGUES AS ANTIBIOTICS AGAINST MULTI-RESISTANT BACTERIA | NOSOPHARM (FR) | 2024-10-03 | — | — | WO | disclosed |
| CN-118251497-A | Lipid compositions comprising peptide-lipid conjugates | 阿克丘勒斯治疗公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-118201639-A | Peptide-lipid conjugates | 阿克丘勒斯治疗公司 | 2024-06-14 | — | — | CN | disclosed |
| EP-4333898-A2 | PEPTIDE-LIPID CONJUGATES | Arcturus Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| WO-2022076621-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2016149628-A1 | TGR5 AGONISTS | CHEMBRIDGE CORPORATION (US) | 2016-09-22 | — | — | WO | disclosed |
| US-8362236-B2 | Macrocyclic compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2013-01-29 | — | — | US | disclosed |
| US-8362236-B2 | Macrocyclic compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2013-01-29 | — | — | US | disclosed |
| EP-2119718-B1 | MACROCYCLIC COMPOUND | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2012-04-11 | — | — | EP | disclosed |
| CN-101687012-A | New cyclic peptide compounds | ASTELLAS PHARMA INC | 2010-03-31 | — | — | CN | disclosed |
| US-20100056510-A1 | Macrocyclic Compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100056510-A1 | Macrocyclic Compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2150269-A1 | NEW CYCLIC PEPTIDE COMPOUNDS | Astellas Pharma Inc. (JP) | 2010-02-10 | — | — | EP | disclosed |
| WO-2008139986-A1 | NEW CYCLIC PEPTIDE COMPOUNDS | ASTELLAS PHARMA INC., (JP) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056510-A1 | Macrocyclic Compound | HSP90AB1, HSP90B1, HSP90AA1 | TDP1 1669/4885MEN1 2984/4885GAA 362/4885 |
| US-20260092053-A1 | KHK INHIBITORS | KHK, SLC5A2, HK1 | TDP1 3648/4885MEN1 4138/4885GAA 1454/4885 |
| US-12410160-B2 | KHK inhibitors | KHK, KHDRBS1, NADK | TDP1 2284/4885MEN1 2989/4885GAA 1257/4885 |
| US-12398154-B2 | Azaquinazoline pan-KRas inhibitors | KRAS, NRAS, HRAS | TDP1 2579/4885MEN1 244/4885GAA 3182/4885 |
| US-20250388606-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | TDP1 3669/4885MEN1 239/4885GAA 4504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.